Guillaume de La Bourdonnaye

Evaluation of the Tobacco Heating System 2.2. Part 8: 5-Day randomized reduced exposure clinical study in Poland

Christelle Haziza, Guillaume de La Bourdonnaye, Dimitra Skiada et al. · Regulatory Toxicology and Pharmacology · 2016 · 122 citations · Full text

Tobacco Cessation, Healthy Subjects, 5-Day Randomized +18

Atacicept in patients with rheumatoid arthritis and an inadequate response to tumor necrosis factor antagonist therapy: Results of a phase II, randomized, placebo-controlled, dose-finding trial

Mark C. Genovese, Nils Kinnman, Guillaume de La Bourdonnaye et al. · Arthritis & Rheumatism · 2011 · 121 citations

Assessment of the reduction in levels of exposure to harmful and potentially harmful constituents in Japanese subjects using a novel tobacco heating system compared with conventional cigarettes and smoking abstinence: A randomized controlled study in confinement

Christelle Haziza, Guillaume de La Bourdonnaye, Sarah Merlet et al. · Regulatory Toxicology and Pharmacology · 2016 · 104 citations · Full text

Tobacco Cessation, Harm Reduction, Japanese Subjects +17

Reduction in Exposure to Selected Harmful and Potentially Harmful Constituents Approaching Those Observed Upon Smoking Abstinence in Smokers Switching to the Menthol Tobacco Heating System 2.2 for 3 Months (Part 1)

Christelle Haziza, Guillaume de La Bourdonnaye, Andrea Donelli et al. · Nicotine & Tobacco Research · 2019 · 87 citations · Full text

Antitumor activity and safety of combination therapy with the Toll-like receptor 9 agonist IMO-2055, erlotinib, and bevacizumab in advanced or metastatic non-small cell lung cancer patients who have progressed following chemotherapy

David A. Smith, Paul Conkling, Donald Richards et al. · Cancer Immunology Immunotherapy · 2014 · 67 citations · Full text

Oncology, Toll-like Receptor 9, Medicine +9